

Title (en)
COMPOSITIONS AND METHODS OF THERAPY FOR CANCERS CHARACTERIZED BY EXPRESSION OF THE TUMOR-ASSOCIATED ANTIGEN MN/CA IX

Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON KREBS, CHARAKTERISIERT DURCH EXPRESSION DES TUMORASSOZIIERTEN ANTIGENS MN/CA IX

Title (fr)
COMPOSITIONS ET PROCEDES THERAPEUTIQUES CONTRE LES CANCERS CARACTERISES PAR L'EXPRESSION DE L'ANTIGENE MN/CA IX ASSOCIE AUX TUMEURS

Publication
EP 1576010 A2 20050921 (EN)

Application
EP 03749129 A 20030825

Priority
• US 0326612 W 20030825
• US 40557702 P 20020823
• US 64693403 A 20030822

Abstract (en)
[origin: WO2004017923A2] Compositions and methods useful in inhibiting proliferation of CA IX + preneoplastic or neoplastic cells in a mammal are provided. The compositions are antagonist anti-CA IX antibodies and other inhibitory agents that target carbonic anhydrase activity of CA IX on these cells. The antagonist anti-CA IX antibodies or antigen-binding fragments thereof are specifically reactive with an inhibitory epitope of CA IX or biologically active variant thereof. Formation of an antibody-antigen complex between the antagonist anti-CA IX antibodies or antigen-binding fragments thereof and the respective inhibitory epitopes results in inhibition of carbonic anhydrase activity of CA IX or biologically active variant thereof. Other small molecule agents that inhibit carbonic anhydrase activity of CA IX or biologically active variant thereof and screening assays for identifying such agents are also provided. The antagonist anti-CA IX antibodies, antigen-binding fragments thereof, and other CA IX inhibitory agents identified herein are useful in the treatment of cancers characterized by the expression of the CA IX tumor-associated antigen.

IPC 1-7
C07K 16/00

IPC 8 full level
C12N 15/09 (2006.01); **A61K 38/00** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 16/00** (2006.01); **C07K 16/30** (2006.01); **C07K 16/40** (2006.01); **C12N 9/88** (2006.01); **C12N 9/99** (2006.01); **C12P 21/08** (2006.01); **C12Q 1/02** (2006.01); **C12Q 1/527** (2006.01); **G01N 33/573** (2006.01)

IPC 8 main group level
A61K (2006.01)

CPC (source: EP)
A61P 35/00 (2017.12); **A61P 43/00** (2017.12); **C07K 16/30** (2013.01); **C07K 16/40** (2013.01)

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2004017923 A2 20040304; **WO 2004017923 A3 20050714**; AU 2003268180 A1 20040311; AU 2003268180 A8 20040311; CA 2496572 A1 20040304; EP 1576010 A2 20050921; EP 1576010 A4 20061227; JP 2005536220 A 20051202

DOCDB simple family (application)
US 0326612 W 20030825; AU 2003268180 A 20030825; CA 2496572 A 20030825; EP 03749129 A 20030825; JP 2004531195 A 20030825